AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03268629 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness-Based Joyful Sleep
Description: The proposed Mindfulness-Based Joyful Sleep program will be conducted weekly, 2 hours per session, 8 sessions, group-based program in mindfulness.
Study NCT03268629 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: CBT-I
Description: The CBT-I program was delivered to groups of 10-15 individuals over the course of eight, weekly, 2-hour sessions, for a total of 16 contact hours.
Study NCT04665596 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound treatment
Description: Ultrasound treatment of calcified aortic valve causing symptomatic aortic valve stenosis in patients who are not eligible for valve replacemen
Study NCT04355273 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: normal saline
Description: normal saline is used for pressurized continuous flushing of the invasive arterial pressure monitoring tube
Study NCT01829048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg (2 mg X 2d, 5 mg X 2d, 8 mg X 3 d, then 15 mg) Q12h
Study NCT01829048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg (5 mg X 2d, 10 mg X 2d, then 15 mg) Q12h
Study NCT01829048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-02545920
Description: 15 mg (5 mg BID for 7 days 10 mg BID for 7 days, then 15 mg BID for 4 days) Q12h
Study NCT01829048 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo Q12h
Study NCT00102635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fenretinide (4-HPR)
Description: Oral 100 mg capsules in two divided doses at least 8 hours apart for 7 days each cycle.
Study NCT00102635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SCH66336
Description: Oral capsules with 50 mg, 75 mg, or 100 mg formulation in two divided doses at least 8 hours apart for 21 days each cycle.
Study NCT00565786 — intervention group
Intervention type: DEVICE
Intervention: ArCom® Polyethylene
Description: Argon packaged compression molded polyethylene
Study NCT00565786 — intervention group
Intervention type: DEVICE
Intervention: ArComXL® Polyethylene
Description: Highly crosslinked Ultra High Molecular Weight Polyethylene
Study NCT04454502 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Oral colostrum administration
Description: In accordance with the oral colostrum protocol, a total of 0.2ml colostrum will be administered into the cheek and on the tongue for the infants weighing between 1001-1500 g.
Study NCT02630654 — intervention group
Intervention type: OTHER
Intervention: This is a non-interventional study. Patients will be treated with any intervention deemed appropriate by the patient's physician.
Study NCT01417663 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Alt-711
Description: Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
Study NCT00977418 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMART- Strategic Memory and Reasoning Training
Description: Teach people to filter out un necessary or unimportant details to enhance mental efficiency. This training will be done over 12 weeks for 3 hours each week.
Study NCT00977418 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical Exercise
Description: The group with undergo 1 hour of aerobic exercise (at 50-70 % of the participants max oxygen intake) 3 times a week for 12 weeks.
Study NCT01417663 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alt-711
Description: Alt-711, also known as Alagebrium, an AGE-crosslink breaker, will be given twice daily 100mg
Study NCT01417663 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Physical exercise training
Description: Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
Study NCT01417663 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Physical exercise training
Description: Exercise training will be given three times a week for 45 minutes per training session. The heart rate reserve will be slowly increased from 70% to 85%.
Study NCT01666977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 15mg/kg
Study NCT06407063 — intervention group
Intervention type: PROCEDURE
Intervention: Micro-decompression alone
Description: In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a midline-preserving decompression without fusion
Study NCT03823924 — intervention group
Intervention type: PROCEDURE
Intervention: Bone mineral density (BMD)
Description: The bone mineral density (BMD) performed by DXA, which will allow the analysis of bone density (mg / cm²) at the lumbar spine (BMD L1 to L4) and the total hip (non-dominant).~This examination will also allow an analysis of the body composition at the same time (lean mass, fat mass and bone mass for the whole body).
Study NCT03435835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Control/Sham Treatment
Description: Water at 33ºC was circulated through water-circulating trousers.
Study NCT03435835 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Heat Therapy (HT)
Description: Water at 42-43ºC was circulated through the water-circulating trousers.
Study NCT04110236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: PriCARE
Description: PriCARE is a group caregiver training program designed to improve child behaviors, caregiver-child relationships, parenting capacity, and reduce caregiver stress. Sessions occur in the primary care clinic or virtually. PriCARE uses the 3 P skills (Praise, Paraphrase and Point-out-Behavior). The training starts with skills on giving attention to children's positive, pro-social behaviors, while ignoring minor misbehaviors. The second part of the training teaches skills for giving effective commands in order to set age-appropriate limits and increase compliance. PriCARE includes a stress education section that contextualizes the use of these skills with the types of behaviors and problems exhibited by many children living with psychosocial adversity and familial stress. Caregivers are encouraged to practice the skills with their child in between sessions. Since PriCARE's initial and successful pilot, the intervention has been enhanced in order to increase engagement and effectiveness.
Study NCT06407063 — intervention group
Intervention type: PROCEDURE
Intervention: Decompression and instrumented fusion
Description: In surgical treatment of Degenerative Spondylolisthesis patients are operated on with a decompression followed by an instrumental fusion with or without an additional cage
Study NCT01666977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386
Description: 30 mg/kg
Study NCT01666977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 386 Placebo
Description: AMG 386 Placebo
Study NCT01666977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed 500 mg/m2
Study NCT04110236 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Positive Discipline Module
Description: The PriCARE Positive Discipline Module is a pilot group caregiver training program designed to teach caregivers positive discipline techniques, including appropriate timeout procedures. The sessions are offered in the primary care setting or virtually. This training will supplement the content of the main PriCARE intervention and provide caregivers with skills for addressing difficult behaviors not reduced through positive attention and strategic ignoring. This module will be offered to a subset of CHOP participants who were randomized to the intervention arm, successfully completed the main study interviews, and attended at least 4 out of the 6 PriCARE sessions.
Study NCT03807180 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tai Chi (exercise)
Description: Tai Chi exercise method, which is composed of combination of physical exercise and relaxation techniques for patients with rheumatic diseases.
Study NCT04306068 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Plyometric protocol
Description: Each session will last 20 minutes, with 2 sessions a week, over a period of 5 weeks. The intervention will last 20 minutes, which consists of a 4-station circuit.~Exercise 1: jump on the rope, with your feet together at a moderate pace. Exercise 2: In standing with hands on the hip and hip flexion (one foot in front). Knee flexion and dorsal ankle flexion, with straight trunk. Alternate legs.~Exercise 3: box jump (jump on the box with both feet at the same time). Exercise 4: depth jumps from box to antoher box (jump on the box with both feet at the same time and when falling, immediately jump to the other box).~1 minute with 30 seconds between sets.
Study NCT01218867 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-VEGFR2 CAR CD8 plus PBL
Description: Patients will receive non-myeloablative lymphodepleting preparative regimen consisting of cyclophosphamide and fludarabine followed by the administration of anti-VEGFR CAR CD8+ PBL and high dose (Arms 1-7) or low dose (Arms 8-11) aldesleukin. On day 0, cells will be infused in the Patient Care Unit over 20-30 minutes (Phase 1: 10e6- 3x10e10 cells and Phase 2: maximum tolerated dose of cells from Phase 1)
Study NCT03628157 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Geistlich Bio-Oss® bovine bone alone
Description: Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
Study NCT03628157 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Geistlich Bio-Oss® bovine bone alone
Description: Ridge augmentation by titanium reinforced polytetraflouroethelene membrane and anorganic bovine bone derived mineral alone
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: COBI
Description: Cobicistat (COBI) 150 mg tablet administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: RTV
Description: Ritonavir (RTV) 100 mg soft gelatin capsule administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ATV
Description: Atazanavir (ATV) 300 mg capsule administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: FTC/TDF
Description: Emtricitabine (FTC) 200 mg/tenofovir disoproxil fumarate (TDF) 300 mg fixed-dose combination tablet administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: COBI placebo
Description: Placebo to match COBI administered orally once daily
Study NCT00892437 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RTV placebo
Description: Placebo to match RTV administered orally once daily
Study NCT00448461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: heparin
Description: comparison between heparin and bivalirudin
Study NCT00448461 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bivalirudin
Description: comparison between heparin and bivalirudin
Study NCT01033994 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: AS902330
Description: 10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Study NCT01033994 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: AS902330
Description: 10, 30 or 100 µg intra-articular injection per subject in the Single Ascending Dose (SAD) cohorts and 10, 30 or 100 µg intra-articular injection per week for three weeks per subject in the Multiple Ascending Dose (MAD) cohorts.
Study NCT03705390 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ILB
Description: Administration will be weekly subcutaneous injections at a dose of 2mg/kg once per week for up to a maximum of 48 weeks
Study NCT04727671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triptorelin acetate
Description: 0.05-0.1 mg subcutaneously (SC) once daily from the mid-luteal phase (day 21) of the cycle until the day of ovulation triggering.
Study NCT04727671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetrorelix
Description: 0.25 mg subcutaneously (SC) once daily starting from the day detecting a leading follicle diameter ≥ 14 mm until the day of ovulation triggering.
Study NCT04727671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04727671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: recombinant-FSH or recombinant-FSH + human Menopausal Gonadotropin
Description: Dosage adjustment according to the ovarian response.
Study NCT04727671 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study NCT04727671 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Human Chorionic Gonadotropin (hCG)
Description: Ovulation will be triggered by the administration of 10,000 IU of Human Chorionic Gonadotropin (hCG) when at least three follicles become more than 16-17 mm.
Study NCT06117514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 30mg
Description: Sudapyridine capsule 30mg, orally, single dose
Study NCT06117514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 100mg SAD
Description: Sudapyridine tablet, 100mg orally, single dose
Study NCT06117514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 200mg SAD
Description: Sudapyridine tablet, 200mg orally, single dose
Study NCT06117514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 200mg MAD
Description: Sudapyridine tablet, 200mg orally once a day for 14 days
Study NCT06117514 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sudapyridine 300mg MAD
Description: Sudapyridine tablet, 300mg orally once a day for 14 days
Study NCT06117514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet SAD
Description: Placebo tablet, 100mg orally, single dose
Study NCT01666977 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 6
Study NCT04085016 — intervention group
Intervention type: DEVICE
Intervention: Keratograph 5M, Oculus, Wetzlar, Germany
Study NCT03014362 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Neuronetics NeuroStar XPLOR magnetic stimulator - Active
Description: Localization: Left prefrontal dorsolateral neocortex. Dose Delivery: Figure-8 solid core coil at 120% motor threshold, 10 Hz, 4 second train duration, 10 second interval for 30 minutes.~Treatment Dose: \~4k/session, 12-15k/day, 36-45k total pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
Study NCT03014362 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Neuronetics NeuroStar XPLOR magnetic stimulator - Sham
Description: Localization: Left prefrontal dorsolateral neocortex. Sham Delivery: Figure-8 solid core coil rendered inert via blocking insert. Dose: Zero pulses. Sessions: 9 in total; 3/day for 3 consecutive days over and above SOC.
Study NCT00408226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MKC-1
Description: capsules, twice daily for 14 days in 21 day cycle
Study NCT00408226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pemetrexed
Description: standard dosing of 500 mg/m2 infused every 21 days
Study NCT03784495 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melatonin 1mg
Description: 1 mg/day 30 minutes before sleep
Study NCT03784495 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Essential Aminoacids (eAA)
Description: 4g/day of Essential Aminoacids during breakfast. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
Study NCT03784495 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: Essential Aminoacids + melatonin
Description: 4g/day of Essential Aminoacids during breakfast + 1 mg/day of Melatonin 30 minutes before sleep. Packets of powdered amino acid supplements (42.0% leucine, 14.0% lysine, 10.5% valine, 10.5% isoleucine, 10.5% threonine, 7.0% phenylalanine, and 5.5% other) were provided for the participants to be taken with water or milk, and they were instructed to take the 4-gram supplement once a day every day for 4 weeks.
Study NCT03784495 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: an isocaloric amount of maltodextrin with the same flavor and appearance as the intervention product
Study NCT03661918 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: In-Person First Session
Description: Conduct first session in person vs. over the phone
Study NCT03661918 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Second Caregiver
Description: Have second caregiver participate in three coaching calls
Study NCT06117514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo 200mg SAD
Description: Placebo tablet, 200mg orally, single dose
Study NCT06117514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet MAD
Description: Placebo tablet, 200mg orally once a day for 14 days
Study NCT06117514 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo tablet MAD
Description: Placebo tablet, 300mg orally once a day for 14 days
Study NCT02725502 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Linagliptin
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with continuous glucose monitoring system (CGMS). Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
Study NCT02725502 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Baseline HbA1C will be assessed. Before starting treatment with linagliptin or placebo. Mixed meal test will be conducted with the standard protocol. Morning dose of insulin to be omitted on the day of mixed meal test. During the mixed meal test glucose, C-peptide, GLP-1 and glucagon will be measured at 0, 30, 60, 120, 180 minutes. 72 hour blood glucose profile to be monitored with CGMS. Markers of glucose control and glucose variability will be measured. Then we will randomly divide these patients in two group (linagliptin and placebo group). After 3 month period 72 hour blood glucose profile, HbA1C and Mixed meal test will be repeated to document any change in blood glucose profile.
Study NCT02302495 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Carfilzomib
Description: DOSING REGIMEN.~The regimen will have 2 parts:~Part 1. Induction. Nine 5 weeks cycles (35-days each) of weekly Carfilzomib Melphalan Prednisone are planned Carfilzomib. 36, 45, 56 or 70 mg/m² on days 1, 8, 15, 22 IV route followed by a 13-day rest period per 35-days cycle. Patients will start the first cycle day 1 with 20mg/m².~In combination with oral Melphalan 0.25mg/kg/j and oral prednisone 60mg/m², both on days 1 to 4.~Part 2. Maintenance. Carfilzomib. 36 mg/m² weekly, every two weeks IV route for 1 year. Melphalan and Prednisone is not pursued at this phase of the study.
Study NCT02351115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: A=Placebo
Study NCT02351115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: B=Inhaled Alprazolam 0.5 mg
Study NCT02351115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: C=Inhaled Alprazolam 1 m
Study NCT02351115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: D= Inhaled Alprazolam 2 mg
Study NCT02351115 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: E=Placebo
Study NCT01053312 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: [18F] Flutemetamol
Description: All subjects will receive an intravenous (IV) dose of \[18F\]flutemetamol (less than 10µg flutemetamol). The nominal activity of a single administration of \[18F\]flutemetamol will be 185 megabecquerels (MBq).
Study NCT01818544 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BAY85-8501
Description: BAY85-8501 (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning
Study NCT01818544 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (1.0 mg, 2 tablets each 0.5 mg) will be administered orally once daily in the morning